Mast cell, a promising therapeutic target in tubulointerstitial fibrosis

Medical Hypotheses

Volumn 69, Issue 1, 2007, Pages 99-103

  Li, Ying ^a   Liu, Fu You ^a   Peng, You Ming ^a   Li, Jun ^a   Chen, Jun ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Center for Disease Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE; ENZYME INHIBITOR; IMMUNOGLOBULIN E ANTIBODY; STEM CELL FACTOR; TRYPTASE;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; ENZYME INHIBITION; FIBROSING ALVEOLITIS; HUMAN; KIDNEY DISEASE; MAST CELL; PRIORITY JOURNAL;

ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG DELIVERY SYSTEMS; FIBROSIS; HUMANS; MAST CELLS; NEPHRITIS, INTERSTITIAL;

EID: 34247570870     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.059     Document Type: Article

References (33)

1. D'Amico G. Tubulointerstitial damage in glomerular diseases: its role in the progression of the renal damage. Nephrol Dial Transplant 13 S1 (1998) 80-85
2. Rodriguez-Iturbe B., Johnson R.J., and Herrera-Acosta J. Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl 99 (2005) S82-S86
3. Rodriguez-Iturbe B., Pons H., Herrera-Acosta J., and Johnson R.J. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59 5 (2001) 1626-1640
4. Okada H., and Kalluri R. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 5 5 (2005) 467-474
5. Vielhauer V., Berning E., Eis V., Kretzler M., Segerer S., Strutz F., et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66 6 (2004) 2264-2278
6. Kitagawa K., Wada T., Furuichi K., Hashimoto H., Ishiwata Y., Asano M., et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165 1 (2004) 237-246
7. Chang C.H., Wang Y.M., Yang A.H., and Chiang S.S. Rapidly progressive interstitial renal fibrosis associated with Chinese herbal medications. Am J Nephrol 21 (2001) 441-448
8. Debelle F.D., Nortier J.L., De Prez E.G., Garbar C.H., Vienne A.R., Salmon I.J., et al. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13 2 (2002) 431-436
9. Hiromura K., Kurosawa M., Yano S., and Naruse T. Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis 32 4 (1998) 593-599
10. Wu Y., Liu Z., Hu W., and Li L. Mast cell infiltration associated with tubulointerstitial fibrosis in chronic aristolochic acid nephropathy. Hum Exp Toxicol 24 2 (2005) 41-47
11. Zoja C., Abbate M., Corna D., Capitanio M., Donadelli R., Bruzzi I., et al. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 31 (1998) 453-463
12. Weber K.T., Swamynathan S.K., Guntaka R.V., and Sun Y. Angiotensin II and extracellular matrix homeostasis. Int J Biochem Cell Biol 31 (1999) 395-403
13. Hollenberg N.K., Fisher N.D., and Price D.A. Pathways for angiotensin II generation in intact human tissue evidence from comparative pharmacological interruption of the renin system. Hypertension 32 (1998) 387-392
14. Yamada M., Ueda M., Naruko T., Tanabe S., Han Y.S., Ikura Y., et al. Mast cell chymase expression and mast cell phenotypes in human rejected kidneys. Kidney Int 59 4 (2001) 1374-1381
15. Toth T., Toth-Jakatics R., Jimi S., Ihara M., Urata H., and Takebayashi S. Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol 10 7 (1999) 1498-1505
16. Yamamoto T., Katayama I., and Nishioka K. Role of mast cells in dermatofibroma: recent viewpoints into the pathogenesis. Eur J Dermatol 13 5 (2003) 419-423
17. Gruber B.L. Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep 5 2 (2003) 147-153
18. Okayama Y., and Kawakami T. Development, migration, and survival of mast cells. Immunol Res 34 2 (2006) 97-115
19. Reber L., Da Silva C.A., and Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533 1-3 (2006) 327-340
20. El Kossi M.M., and El Nahas A.M. Stem cell factor and crescentic glomerulonephritis. Am J Kidney Dis 41 4 (2003) 785-795
21. El-Koraie A.F., Baddour N.M., Adam A.G., El Kashef E.H., and El Nahas A.M. Role of mast cells in the progression of chronic glomerulonephritides. Kidney Int 60 (2001) 167-172
22. Otsubo S., Nitta K., Uchida K., Yumura W., and Nihei H. Mast cells and tubulointerstitial fibrosis in patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol 7 1 (2003) 41-47
23. Miyajima A., Asano T., Asano T., Yoshimura I., Seta K., and Hayakawa M. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction. J Urol 165 (2001) 1714-1718
24. Kelly D.J., Zhang Y., Gow R., and Gilbert R.E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 15 10 (2004) 2619-2629
25. Soma J., Sugawara T., Huang Y.D., Nakajima J., and Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 92 (2002) 693-698
26. Mifsud S., Kelly D.J., Qi W., Zhang Y., Pollock C.A., Wilkinson-Berka J.L., et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron 95 (2003) 83-91
27. Qi W., Chen X., Twigg S., Polhill T.S., Gilbert R.E., and Pollock C.A. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 69 6 (2006) 989-995
28. Jones S.E., Gilbert R.E., and Kelly D.J. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. J Diab Comp 18 5 (2004) 309-315
29. Doggrell S.A., and Wanstall J.C. Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can J Physiol Pharmacol 83 2 (2005) 123-130
30. Shiota N., Kakizoe E., Shimoura K., Tanaka T., and Okunishi H. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br J Pharmacol 145 4 (2005) 424-431
31. Finotto S., Buerke M., Lingnau K., Schmitt E., Galle P.R., and Neurath M.F. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol 107 2 (2001) 279-286
32. Finotto S., Mekori Y.A., and Metcalfe D.D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 99 (1997) 1721-1728
33. Reber L., Da Silva C.A., and Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 533 1-3 (2006) 327-340